(Q44411568)

2 December 2017

0 references

Tissue necrosis factor α and targeting its receptor in ischaemic heart disease (English)

1 reference

2 December 2017

1

David J Moliterno

1 reference

2 December 2017

2

Susan S Smyth

1 reference

2 December 2017

language of work or name

English

0 references

publication date

22 May 2013

1 reference

2 December 2017

1 reference

2 December 2017

volume

99

1 reference

2 December 2017

issue

18

1 reference

2 December 2017

page(s)

1305-1306

1 reference

Regulation of the inflammatory response in cardiac repair

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Meta-analysis of corticosteroid treatment in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-303960

10.1136/HEARTJNL-2013-303960

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference